Black Diamond Therapeutics, Inc. - Common Stock (BDTX)

Q4 2021 13F Holders as of 31 Dec 2021

Type / Class
Equity / Common Stock
Shares outstanding
56,078,244
Total 13F shares
20,172,596
Share change
-1,396,663
Total reported value
$107,500,132
Put/Call ratio
319%
Price per share
$5.33
Number of holders
77
Value change
-$13,365,863
Number of buys
30
Number of sells
51

Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q4 2021

As of 31 Dec 2021, Black Diamond Therapeutics, Inc. - Common Stock (BDTX) was held by 77 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 20,172,596 shares. The largest 10 holders included Bellevue Group AG, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., BOXER CAPITAL, LLC, Artal Group S.A., FEDERATED HERMES, INC., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, and STATE STREET CORP. This page lists 78 institutional shareholders reporting positions in this security for the Q4 2021 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.